The Burkitt-like lymphomas: A Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features

Blood

Volumn 97, Issue 12, 2001, Pages 3713-3720

  Braziel, Rita M ^{a,b,c,d,e,f,g,h,i,j}   Arber, Daniel A ^{a,b,c,d,e,f,g,h,i}   Slovak, Marilyn L ^{a,b,c,d,e,f,g,h,i}   Gulley, Margaret L ^{a,b,c,d,e,f,g,h,i}   Spier, Catherine ^{a,b,c,d,e,f,g,h,i}   Kjeldsberg, Carl ^{a,b,c,d,e,f,g,h,i}   Unger, Joseph ^{a,b,c,d,e,f,g,h,i}   Miller, Thomas P ^{a,b,c,d,e,f,g,h,i}   Tubbs, Raymond ^{a,b,c,d,e,f,g,h,i}   Leith, Catherine ^{a,b,c,d,e,f,g,h,i}   Fisher, Richard I ^{a,b,c,d,e,f,g,h,i}   Grogan, Thomas M ^{a,b,c,d,e,f,g,h,i}  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

^e UNIVERSITY OF UTAH   (United States)

^f SWOG STATISTICAL CENTER   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

^h UNIVERSITY OF NEW MEXICO   (United States)

ⁱ LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^j OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD18 ANTIGEN; CD8 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; HERMES ANTIGEN; HOMING RECEPTOR; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; KI 67 ANTIGEN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; PROTEIN BCL 2; PROTEIN P53;

ADULT; ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER CLASSIFICATION; CANCER GRADING; CANCER GROWTH; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; FEMALE; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME;

EID: 0035877997     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.12.3713     Document Type: Article

References (47)

1. Harris N, Jaffe E, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the international Lymphoma Study Group. Blood. 1994;84:1361-1392.
2. The Non-Hodgkin's Lymphoma Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer. 1982;49:2112-2135.
3. Grogan T, Warnke R, Kaplan H. A comparative study of Burkitt's and non-Burkitt's "undifferentiated" malignant lymphoma: immunologic, cytochemical, ultrastructural, cytologic, histopathologic, clinical and cell culture features. Cancer. 1982;49:1817-1828.
4. Payne C, Grogan T, Cromey D, Bjore C, Kerrigan D. An ultrastructural morphometric and immunophenotypic evaluation of Burkitt's and Burkitt's-like lymphomas. Lab Invest. 1987;57:200-218.
5. Hutchison R, Murphy S, Fairclough D, et al. Diffuse small noncleaved cell lymphoma in children: Burkitt's versus non-Burkitt's types. Cancer. 1989;64:23-28.
6. Wilson JF, Kjeldsberg CR, Sposto R, et al. The pathology of non-Hodgkin's lymphoma of childhood. II. Reproducibility and relevance of the histologic classification of "undifferentiated" lymphomas (Burkitt's versus non-Burkitt's). Hum Pathol. 1987;18:1008-1014.
7. The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood. 1997;89:3909-3918.
8. Fisher R, Gaynor E, Dahlberg S, et al. Comparison of standard (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328:1002-1007.
9. Miller T, Grogan T, Dahlberg S, et al. Prognostic significance of the Ki-67 associated proliferation antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group Trial. Blood. 1994;83:1460-1466.
10. Fan H, Gulley ML. In situ hybridization to EBER transcripts. In: Killeen A, ed. Molecular Pathology Protocols. Totowa, NJ: Humana Press; 2001:301-311.
11. Ambinder RF, Mann RB. Detection and characterization of Epstein-Barr virus in clinical specimens. Am J Pathol. 1994;145:239-252.
12. Hedley D, Friedlander M, Taylor I, Rugg C, Musgrove E. Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem. 1983;31:1333-1335.
13. Liehr T, Grehl H, Rautenstrauss B. FISH analysis of interphase nuclei from paraffin-embedded tissue. Trends Genet. 1995;11:377-378.
14. Veronese M, Ohta M, Finan J, Nowell P, Croce C. Detection of myc translations in lymphoma cells by fluorescence in situ hybridization with yeast artificial chromosomes. Blood. 1995;85:2132-2138.
15. Lengauer C, Green E, Cremer T. Fluorescence in situ hybridization of YAC clones after Alu-PCR amplification. Genomics. 1992;13:826-828.
16. Zhang F, Arber D, Wilson T, Kawachi M, Slovak M. Toward the validation of aneusomy detection by fluorescence in situ hybridization in bladder cancer: comparative analysis with cytology, cytogenetics, and clinical features predicts recurrence and defines clinical testing limitations. Clin Cancer Res. 1997;3:2317-2328.
17. Liu J, Johnson RM, Traweek ST. Rearrangement of the BCL-2 gene in follicular lymphoma: detection by PCR in both fresh and fixed tissue samples. Diagn Mol Pathol. 1993;2:241-247.
18. Lawn RM, Efstratiadis A, O'Connell C, Maniatis T. The nucleotide sequence of the human β-globin gene. Cell. 1980;21:647-651.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
20. Farrell PJ, Allan GJ, Shanahan F, Vousden KH, Crook T. P53 is frequently mutated in Burkitt's lymphoma cell lines. EMBO J. 1991;10:2879-2882.
21. Bhatia KS, Gutierrez MI, Hippi D, Siwarski D, Magrath IT. The pattern of p53 mutations in Burkitt's lymphoma differs from that of solid tumors. Cancer Res. 1992;52:4273-4276.
22. Magrath I. The pathogenesis of Burkitt's lymphoma. In: Van de Woude GF, Klein G, eds. Advances of Cancer Research. London, England: Academic Press; 1990:133-270.
23. Tao Q, Robertson K, Manns A, Hildesheim A, Ambinder R. Epstein-Barr (EBV) in endemic Burkitt's lymphoma: molecular analysis of primary tumor tissue. Blood. 1998;91:1373-1381.
24. Niedobitek G, Agathanggelou A, Rowe M, et al. Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma. Blood. 1995;86:659-665.
25. Garcia C, Weiss L, Warnke R. Small noncleaved cell lymphoma: an immunophenotypic study of 18 cases and comparison with large cell lymphoma. Hum Pathol. 1986;17:454-461.
26. Yunis JJ, Mayer MG, Arnesen MA, Aeppli DP, Oken MM, Frizzera G. Bcl-2 and other genomic alterations in the prognosis of large cell lymphoma. N Engl J Med. 1989;320:1047-1054.
27. Schouten HC, Sanger WG, Weisenburger DD, Anderson J, Armitage JO, for the Nebraska Lymphoma Study Group. Chromosomal abnormalities in untreated patients with non-Hodgkin's lymphoma: associations with histology, clinical characteristics, and treatment outcome. Blood. 1990;75:1841-1847.
28. Tang SC, Visser L, Hepperle B, Hanson J, Poppema S. Clinical significance of bcl-2-MBR gene rearrangement and protein expression in diffuse large cell non-Hodgkin's lymphoma: an analysis of 83 cases. J Clin Oncol. 1994;12:149-154.
29. Gascoyne R, Adomat S, Krajewski S, et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood. 1997;90:244-251.
30. Kramer M, Wijburg H, Philippo W, et al. Clinical relevance of BCL-2, BCL-6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood. 1998;92:3152-3162.
31. Morrison V, Frizzera G, Arthur D, et al. Prognostic factors for therapeutic outcome of diffuse small non-cleaved cell lymphoma in adults. Am J Hematol. 1994;46:295-303.
32. The Fifth International Workshop on Chromosomes in Leukemia-Lymphoma. Correlation of chromosome abnormalities with histologic and immunologic characteristics in non-Hodgkin's lymphoma and adult T-cell leukemia-lymphoma. Blood. 1987;70:1554-1564.
33. Douglass E, Magrath I, Lee E, Whang-Peng J. Cytogenetic studies in non-African Burkitt lymphoma. Blood. 1980;55:148-155.
34. Aiello A, Delia D, Fontanella E, Giardini R, Rilke F, Della Porta G. Expression of differentiation and adhesion molecules in sporadic Burkitt's lymphoma. Hematol Oncol. 1990;8:229-238.
35. Billaud M, Rousset F, Calender A, et al. Low expression of lymphocyte function-associated antigen (LFA)-1 and LFA-3 adhesion molecules is a common trait in Burkitt's lymphoma associated with and not associated with Epstein-Barr virus. Blood. 1990;75:1827-1833.
36. Horst E, Meijer C, Radaszkiewicz T, Ossekoppele G, Van Krieken J, Pals S. Adhesion molecules in the prognosis of diffuse large cell lymphoma: expression of a lymphocyte homing receptor (CD44), LFA-1 (CD11a/18), and ICAM-1 (CD54). Leukemia. 1990;4:595-599.
37. Maio M, Pinto A, Carbone A, et al. Differential expression of CD54/intercellular adhesion molecule-1 in myeloid leukemias and in lymphoproliferative disorders. Blood. 1990;76:783-790.
38. Mielcarek M, Sperling C, Schrappe M, Meyer U, Riehn H, Ludwig W. Expression of intercellular adhesion molecule 1 (ICAM-1) in childhood acute lymphoblastic leukaemia: correlation with clinical features and outcome. Br J Hematol. 1997;96:301-307.
39. Stauder R, Greil R, Schulz F, et al. Expression of leucocyte function-associated antigen-1 and 7F7-antigen, and adhesion molecule related to intercellular adhesion molecule-1 (ICAM-1) in non-Hodgkin's lymphomas and leukaemias: possible influence on growth pattern and leukaemic behavior. Clin Exp Immunol. 1989;77:234-238.
40. Gregory CD, Murray RJ, Edwards CF, Rickinson AB. Down-regulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T-cell surveillance. J Exp Med. 1988;167:1811-1824.
41. List AF, Spier CM, Miller TP, Grogan TM. Deficient tumor-infiltrating T-lymphocyte response in malignant lymphoma: relationship to HLA expression and host immunocompetence. Leukemia. 1993;7:398-403.
42. Yano T, van Krieken J, Magrath IT, Longo DL, Jaffe ES, Raffeld M. Histogenetic correlations between subcategories of small noncleaved cell lymphomas. Blood. 1992;79:1282-1290.
43. Armitage JO, Weisenburger DD, for the Non-Hodgkin's Lymphoma Classification Project. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. J Clin Oncol. 1998;16:2780-2795.
44. Chai C, Aoun P, Greiner T, et al. BCL6 and P53 gene expression predict survival in the small non-cleaved cell lymphomas [abstract]. Mod Pathol. 1999;12:133A.
45. Miller TP, Lippman SM, Spier CM. HLA-DR immune phenotype predicts outcome for patients with diffuse large cell lymphoma. J Clin Invest. 1988;82:370-372.
46. Slymen DJ, Miller TP, Lippman SM. Immunobiologic factors predictive of clinical outcome in diffuse large cell lymphoma. J Clin Oncol. 1990;8:985-993.
47. Jaffe ES, Harris NL, Diebold J, Muller-Hermelink HK. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissue: a progress report. Am J Clin Pathol. 1999;111(suppl 1):S8-S12.